{"title":"Efficacy and Safety of Montelukast Sodium Tablets Combined with Budesonide Suspension in the Treatment of Patients with Bronchial Asthma","authors":"Deyun Liu, Dawei Fei","doi":"10.1007/s11094-024-03156-4","DOIUrl":null,"url":null,"abstract":"<p>To evaluate the efficacy and safety of montelukast sodium tablets combined with budesonide suspension in the treatment of patients with bronchial asthma, ninety patients with bronchial asthma treated in The People’s Hospital of Quanjiao from January 2018 to April 2021 were randomly included in the study and then randomly divided into an observation group and a control group with 45 cases in each group. Patients in both groups were given clinical routine and symptomatic treatment. Patients in the control group were given budesonide suspension treatment on the basis of routine treatment, and patients in the observation group were treated with montelukast sodium tablets on the basis of the control group. The daytime and nighttime cough scores and asthma control scores (ACT scores) of the two groups were recorded before and after treatment. The pulmonary function indexes such as forced expiratory volume in one second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEFR), etc., were measured. The daytime cough score and nighttime cough score of the patients in the observation group after treatment were significantly lower than those before treatment and the control group at the same period, and the act score was significantly higher than that before treatment and the control group during the same period (<i>P</i> < 0.05). FEV1, FVC, PEFR and other pulmonary function indexes were significantly better than those before treatment and the control group at the same period (<i>P</i> < 0.05). The total clinical effective rate of the observation group was 93.33%, which was significantly higher than 71.11% of the control group (<i>P</i> < 0.05). There was no significant difference in the incidence of adverse reactions between the other two groups (<i>P</i> > 0.05). Montelukast sodium tablets combined with budesonide suspension can effectively improve cough, asthma symptoms and lung function of patients with bronchial asthma.</p>","PeriodicalId":19990,"journal":{"name":"Pharmaceutical Chemistry Journal","volume":"30 1","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Chemistry Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11094-024-03156-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
To evaluate the efficacy and safety of montelukast sodium tablets combined with budesonide suspension in the treatment of patients with bronchial asthma, ninety patients with bronchial asthma treated in The People’s Hospital of Quanjiao from January 2018 to April 2021 were randomly included in the study and then randomly divided into an observation group and a control group with 45 cases in each group. Patients in both groups were given clinical routine and symptomatic treatment. Patients in the control group were given budesonide suspension treatment on the basis of routine treatment, and patients in the observation group were treated with montelukast sodium tablets on the basis of the control group. The daytime and nighttime cough scores and asthma control scores (ACT scores) of the two groups were recorded before and after treatment. The pulmonary function indexes such as forced expiratory volume in one second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEFR), etc., were measured. The daytime cough score and nighttime cough score of the patients in the observation group after treatment were significantly lower than those before treatment and the control group at the same period, and the act score was significantly higher than that before treatment and the control group during the same period (P < 0.05). FEV1, FVC, PEFR and other pulmonary function indexes were significantly better than those before treatment and the control group at the same period (P < 0.05). The total clinical effective rate of the observation group was 93.33%, which was significantly higher than 71.11% of the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the other two groups (P > 0.05). Montelukast sodium tablets combined with budesonide suspension can effectively improve cough, asthma symptoms and lung function of patients with bronchial asthma.
期刊介绍：
Pharmaceutical Chemistry Journal is a monthly publication devoted to scientific and technical research on the creation of new drugs and the improvement of manufacturing technology of drugs and intermediates. International contributors cover the entire spectrum of new drug research, including:
methods of synthesis;
results of pharmacological, toxicological, and biochemical studies;
investigation of structure - activity relationships in prediction of new compounds;
methods and technical facilities used; and
problems associated with the development of ecologically safe and economically feasible methods of industrial production.
In addition, analytical reviews of the international literature in the field provide coverage of the most recent developments around the world.
Pharmaceutical Chemistry Journal is a translation of the Russian journal Khimiko-Farmatsevticheskii Zhurnal. The Russian Volume Year is published in English from April.
All articles are peer-reviewed.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
